Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Closes
- Nov 5, 2027 (in 432 days)
Similar opportunities open now
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses in 86 days
- Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 2028
- Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Mar 2027Up to $500K
- First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jul 2028
Classification and identifiers
- Solicitation number
- PAR-25-149
- Assistance listing (CFDA)
- 93.853
Amount
Amount not published by the funder
Who can apply
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
About this opportunity
This limited competition Notice of Funding Opportunity (NOFO) invites renewal applications of existing NINDS-supported clinical trial cooperative agreement awards (U01) requiring additional time and resources to complete the clinical trial.